Eli Lilly’s ongoing technology evaluation agreement with Peptron, set to conclude October 7, 2026, remains strictly limited to non-binding feasibility studies of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates, including GLP-1 agents. This structure grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing, which would require a separate binding deal. Recent expansions into CNS indications and completed initial in-vivo validation show technical progress, yet Lilly continues parallel development with alternative long-acting delivery systems such as Camurus’ FluidCrystal. With the deadline days away and no disclosed shift to a technology transfer agreement, trader consensus heavily favors no licensing outcome by the resolution date.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于13% 概率
$11,464 交易量
$11,464 交易量
2026-10-07
13% 概率
$11,464 交易量
$11,464 交易量
2026-10-07
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, set to conclude October 7, 2026, remains strictly limited to non-binding feasibility studies of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates, including GLP-1 agents. This structure grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing, which would require a separate binding deal. Recent expansions into CNS indications and completed initial in-vivo validation show technical progress, yet Lilly continues parallel development with alternative long-acting delivery systems such as Camurus’ FluidCrystal. With the deadline days away and no disclosed shift to a technology transfer agreement, trader consensus heavily favors no licensing outcome by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
市场开放时间： May 5, 2026, 8:02 PM ET
交易量
$11,464结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETThis market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron, set to conclude October 7, 2026, remains strictly limited to non-binding feasibility studies of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates, including GLP-1 agents. This structure grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing, which would require a separate binding deal. Recent expansions into CNS indications and completed initial in-vivo validation show technical progress, yet Lilly continues parallel development with alternative long-acting delivery systems such as Camurus’ FluidCrystal. With the deadline days away and no disclosed shift to a technology transfer agreement, trader consensus heavily favors no licensing outcome by the resolution date.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
交易量
$11,464结束日期
2026-10-07市场开放时间
May 5, 2026, 8:02 PM ETEli Lilly’s ongoing technology evaluation agreement with Peptron, set to conclude October 7, 2026, remains strictly limited to non-binding feasibility studies of the SmartDepot sustained-release microsphere platform on Lilly’s peptide candidates, including GLP-1 agents. This structure grants only internal R&D rights, permits termination on 30 days’ notice, and explicitly excludes commercial licensing, which would require a separate binding deal. Recent expansions into CNS indications and completed initial in-vivo validation show technical progress, yet Lilly continues parallel development with alternative long-acting delivery systems such as Camurus’ FluidCrystal. With the deadline days away and no disclosed shift to a technology transfer agreement, trader consensus heavily favors no licensing outcome by the resolution date.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题